Mankan N, Nooka AK. Improvements in myeloma specific survival over the last two decades. J Clin Oncol. 2022;40(16_suppl):e18503–e18503.

Article  Google Scholar 

Al Hadidi S, Ababneh OE, Schinke CD, Thanendrarajan S, Siegel ER, Bailey C, et al. Long-Term Follow-Up of patients with multiple myeloma treated on earlier total therapy protocols: A secondary analysis of 3 clinical trials. JAMA Oncol. 2025;11(8):910–5.

Article  PubMed  PubMed Central  Google Scholar 

Munshi NC, Anderson LD, Shah N, Madduri D, Berdeja J, Lonial S, et al. Idecabtagene vicleucel in relapsed and refractory multiple myeloma. N Engl J Med. 2021;384(8):705–16.

Article  CAS  PubMed  Google Scholar 

San-Miguel J, Dhakal B, Yong K, Spencer A, Anguille S, Mateos MV, et al. Cilta-cel or Standard Care in Lenalidomide-Refractory Multiple Myeloma. N Engl J Med. 27(4):335–47.

Dimopoulos MA, Beksac M, Pour L, Delimpasi S, Vorobyev V, Quach H, et al. Belantamab Mafodotin, Pomalidomide, and Dexamethasone in Multiple Myeloma. N Engl J Med. 31(5):408–21.

Moreau P, Garfall AL, van de Donk NWCJ, Nahi H, San-Miguel JF, Oriol A, et al. Teclistamab in relapsed or refractory multiple myeloma. N Engl J Med. 2022;387(6):495–505.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Chari A, Minnema MC, Berdeja JG, Oriol A, Donk NWCJ, van de, Rodríguez-Otero P, et al. Talquetamab, a T-Cell–Redirecting GPRC5D bispecific antibody for multiple myeloma. N Engl J Med. 2022;387(24):2232–44.

Article  CAS  PubMed  Google Scholar 

Kumar S, Paiva B, Anderson KC, Durie B, Landgren O, Moreau P, et al. International myeloma working group consensus criteria for response and minimal residual disease assessment in multiple myeloma. Lancet Oncol. 2016;17(8):e328–46.

Article  PubMed  Google Scholar 

de Tute RM, Pawlyn C, Cairns DA, Davies FE, Menzies T, Rawstron A et al. Minimal Residual Disease After Autologous Stem-Cell Transplant for Patients With Myeloma: Prognostic Significance and the Impact of Lenalidomide Maintenance and Molecular Risk. J Clin Oncol Off J Am Soc Clin Oncol. 2022 Sept 1;40(25):2889–900.

Cavo M, San-Miguel J, Usmani SZ, Weisel K, Dimopoulos MA, Avet-Loiseau H, et al. Prognostic value of minimal residual disease negativity in myeloma: combined analysis of POLLUX, CASTOR, ALCYONE, and MAIA. Blood. 2022;139(6):835–44.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Pasquini MC, Wallace PK, Logan B, Kaur M, Tario JD, Howard A, et al. Minimal residual disease status in multiple myeloma 1 year after autologous hematopoietic cell transplantation and Lenalidomide maintenance are associated with Long-Term overall survival. J Clin Oncol Off J Am Soc Clin Oncol. 2024;42(23):2757–68.

Article  CAS  Google Scholar 

Shah Z, Khan I, Selene II, Waqar SHB, Khanam R, Abid Q, ul ain, et al. The association between minimal residual disease status and survival outcomes in transplant-ineligible newly diagnosed multiple myeloma (TIE-NDMM) patients: Systematic review. J Clin Oncol. 40(16suppl):e20009-20009.

Am BDNK, El L, U S et al. S, S M,. Dynamics of minimal residual disease in patients with multiple myeloma on continuous lenalidomide maintenance: a single-arm, single-centre, phase 2 trial. Lancet Haematol [Internet]. 2021 June [cited 2025 Oct 25];8(6). Available from: https://pubmed.ncbi.nlm.nih.gov/34048681/

Ntanasis-Stathopoulos I, Filippatos C, Ntanasis-Stathopoulos A, Malandrakis P, Kastritis E, Tsitsilonis OE, et al. Evaluating minimal residual disease negativity as a surrogate endpoint for treatment efficacy in multiple myeloma: a meta-analysis of randomized controlled trials. Am J Hematol. 2025;100(3):427–38.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Xu W, Liang X, Liu S, Yi X, Tian M, Yue T, et al. Dynamics of minimal residual disease and its clinical implications in multiple myeloma: a retrospective real-life analysis. Clin Med. 2024;24(6):100252.

Article  Google Scholar 

Mohan M, Kendrick S, Szabo A, Yarlagadda N, Atwal D, Pandey Y, et al. Clinical implications of loss of bone marrow minimal residual disease negativity in multiple myeloma. Blood Adv. 2022;6(3):808–17.

Article  PubMed  PubMed Central  Google Scholar 

Costa LJ, Chhabra S, Medvedova E, Dholaria BR, Schmidt TM, Godby KN, et al. Minimal residual disease response-adapted therapy in newly diagnosed multiple myeloma (MASTER): final report of the multicentre, single-arm, phase 2 trial. Lancet Haematol. 2023;10(11):e890–901.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Perrot A, Lambert J, Hulin C, Pieragostini A, Karlin L, Arnulf B, et al. Measurable Residual Disease–Guided Therapy in Newly Diagnosed Myeloma. N Engl J Med. 30(5):425–37.

Askeland FB, Rasmussen AM, Lysen A, Haukås E, Eilertsen AL, Moksnes M, et al. Will survival improve by treating multiple myeloma patients at MRD relapse? The remnant study. Blood. 2023;142(Supplement 1):4755.

Article  Google Scholar 

Derman BA, Major A, Cooperrider J, Jiang K, Ramsland A, Karrison T, et al. Discontinuation of maintenance therapy in multiple myeloma guided by multimodal measurable residual disease negativity (MRD2STOP). Blood Cancer J. 2024;14(1):170.

Article  PubMed  PubMed Central  Google Scholar 

Adan A, Alizada G, Kiraz Y, Baran Y, Nalbant A. Flow cytometry: basic principles and applications. Crit Rev Biotechnol. 2017;37(2):163–76.

Article  CAS  PubMed  Google Scholar 

Bataille R, Jégo G, Robillard N, Barillé-Nion S, Harousseau JL, Moreau P, et al. The phenotype of normal, reactive and malignant plasma cells. Identification of many and multiple myelomas and of new targets for myeloma therapy. Haematologica. 91(9):1234–40.

Robillard N, Wuillème S, Moreau P, Béné MC. Immunophenotype of normal and myelomatous plasma-cell subsets. Front Immunol. 2014;5:137.

Article  PubMed  PubMed Central  Google Scholar 

Flores-Montero J, de Tute R, Paiva B, Perez JJ, Böttcher S, Wind H, et al. Immunophenotype of normal vs. myeloma plasma cells: toward antibody panel specifications for MRD detection in multiple myeloma. Cytometry B Clin Cytom. 2016;90(1):61–72.

Article  CAS  PubMed  Google Scholar 

Flores-Montero J, Sanoja-Flores L, Paiva B, Puig N, García-Sánchez O, Böttcher S, et al. Next generation flow for highly sensitive and standardized detection of minimal residual disease in multiple myeloma. Leukemia. 2017;31(10):2094–103.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Paiva B, Puig N, Cedena MT, Rosiñol L, Cordón L, Vidriales MB, et al. Measurable residual disease by Next-Generation flow cytometry in multiple myeloma. J Clin Oncol. 2020;38(8):784–92.

Article  CAS  PubMed  Google Scholar 

Bai Y, Orfao A, Chim CS. Molecular detection of minimal residual disease in multiple myeloma. Br J Haematol. 2018;181(1):11–26.

Article  CAS  PubMed  Google Scholar 

Sarasquete ME, García-Sanz R, González D, Martínez J, Mateo G, Martínez P, et al. Minimal residual disease monitoring in multiple myeloma: a comparison between allelic-specific oligonucleotide real-time quantitative polymerase chain reaction and flow cytometry. Haematologica. 2005;90(10):1365–72.

CAS  PubMed  Google Scholar 

Takamatsu H. Comparison of Minimal Residual Disease Detection by Multiparameter Flow Cytometry, ASO-qPCR, Droplet Digital PCR, and Deep Sequencing in Patients with Multiple Myeloma Who Underwent Autologous Stem Cell Transplantation. J Clin Med. 2017(10):91.

Puig N, Sarasquete ME, Balanzategui A, Martínez J, Paiva B, García H, et al. Critical evaluation of ASO RQ-PCR for minimal residual disease evaluation in multiple myeloma. A comparative analysis with flow cytometry. Leukemia. 2014;28(2):391–7.

Article  CAS  PubMed  Google Scholar 

Ferla V, Antonini E, Perini T, Farina F, Masottini S, Malato S, et al. Minimal residual disease detection by next-generation sequencing in multiple myeloma: promise and challenges for response-adapted therapy. Front Oncol. 2022;12:932852.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Oliva S, Genuardi E, Paris L, D’Agostino M, Rogers J, Rota-Scalabrini D, et al. Prospective evaluation of minimal residual disease in the phase II FORTE trial: a head-to-head comparison between multiparameter flow cytometry and next-generation sequencing. EClinicalMedicine. 60:102016.

Avet-Loiseau H, Bene MC, Wuilleme S, Corre J, Attal M, Arnulf B, et al. Concordance of Post-consolidation minimal residual disease rates by multiparametric flow cytometry and Next-generation sequencing in CASSIOPEIA. Clin Lymphoma Myeloma Leuk. 2019;19(10):e3–4.

Article  Google Scholar 

Kyle RA, Gertz MA, Witzig TE, Lust JA, Lacy MQ, Dispenzieri A, et al. Review of 1027 patients with newly diagnosed multiple myeloma. Mayo Clin Proc. 2003;78(1):21–33.

Article  PubMed  Google Scholar 

Tsui AKY, Thomas D, Hunt A, Estey M, Christensen CL, Higgins T, et al. Analytical sensitivity and diagnostic performance of serum protein electrophoresis on the HYDRAGEL 30 PROTEIN(E) β1-β2 Sebia Hydrasys system. Clin Biochem. 2018;51:80–4.

Article  CAS  PubMed  Google Scholar 

Jacobs JFM, Turner KA, Graziani MS, Frinack JL, Ettore MW, Tate JR, et al. An international multi-center serum protein electrophoresis accuracy and M-protein isotyping study. Part II: limit of detection and follow-up of patients with small M-proteins. Clin Chem Lab Med. 2020;58(4):547–59.

Article  CAS  PubMed  Google Scholar 

Zajec M, Langerhorst P, VanDuijn MM, Gloerich J, Russcher H, van Gool AJ, et al. Mass spectrometry for Identification, Monitoring, and minimal residual disease detection of M-Proteins. Clin Chem. 2020;66(3):421–33.

Article  CAS  PubMed  Google Scholar 

Murray DL, Puig N, Kristinsson S, Usmani SZ, Dispenzieri A, Bianchi G, et al. Mass spectrometry for the evaluation of monoclonal proteins in multiple myeloma and related disorders: an international myeloma working group mass spectrometry committee report. Blood Cancer J. 2021;11(2):24.